After BLENREP was pulled in November of 2022 from the U.S. myeloma treatment market, patients, caregivers, and physicians alike felt the keen disappointment of losing a therapy designed to treat multiple myeloma.

While losing a myeloma medication isn't unheard of, with the recent progress of approvals in the treatment field, it's a reminder that we need as many therapies as possible to treat each patient's unique myeloma. 

Now, a year later, GSK is announcing the positive results of DREAMM-7, a phase III clinical trial comparing BLENREP BorDex (belantamab-mafodotin, bortezomib, and dexamethasone) to daratumumab (Darzalex) plus bortezomib and dexamethasone. This puts hope back on the horizon for a potential reapproval from the FDA. 

This clinical trial was designed as a second-line therapy comparison for those with relapsed/refractory disease. This randomized trial compared the two regimens in 494 myeloma patients. These participants has previously been treated with at least one line of multiple myeloma therapy with documented disease progression during or after their most recent therapy. 

The results showed significant PFS (progression-free survival) benefits for those in the BLENREP BorDex arm versus the daratumamab plus BorDex arm. A strong (and clinically meaningful) OS, or overall survival) trend was also observed, and the trial continues to prove that trend. 

According to the GSK website, for those unfamiliar with BLENREP: 

Blenrep is an antibody-drug conjugate comprising a humanised B-cell maturation antigen monoclonal antibody conjugated to the cytotoxic agent auristatin F via a non-cleavable linker. The drug linker technology is licensed from Seagen Inc.; the monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa Inc., a member of the Kyowa Kirin Group.

Learn more about the trial, treatment, company, and multiple myeloma by reading the official media press release here: GSK Press Release BLENREP Update